Clinical Trial Update: Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants [Phase 2, Phase 3]

View source ↗

Summary

The Phase 2/3 study of cellular immunotherapy in HLA-mismatched living donor kidney transplant recipients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection

Drugs mentioned

• Cellular immunotherapy (unspecified)

Snippet

Sponsor: Medeor Therapeutics, Inc. | Conditions: Kidney Transplant Rejection | Phase 2, Phase 3 | Status: WITHDRAWN